Children living with a serious heart condition now have a new treatment option. The FDA has expanded its approval of mavacamten to include eligible pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy, or HCM.
The 2026 approval allows children weighing at least 66 pounds to receive the medication, which was previously approved for adults. The decision marks an important development for young patients and families navigating a condition that can significantly affect heart function and daily life.
The Burden of Pediatric HCM
Hypertrophic cardiomyopathy is the most common inherited heart disorder. It causes the heart muscle to become abnormally thick, making it harder for the heart to function properly. In obstructive HCM, the thickened muscle can also restrict blood flow out of the heart.
For children living with the condition, symptoms may include shortness of breath, fatigue, chest pain or difficulty participating in physical activities. Some patients face more serious complications, including abnormal heart rhythms and heart failure.
These challenges can be particularly difficult during childhood and adolescence, when school, sports and other activities play an important role in development. Managing the condition often requires ongoing monitoring and specialized cardiac care.
Previously, treatment options specifically approved for pediatric patients with obstructive HCM were limited. The expanded approval of mavacamten offers clinicians another option to consider when developing treatment plans for eligible young patients.
Progress for Young Patients
Mavacamten is a cardiac myosin inhibitor that works by reducing excessive contraction of the heart muscle. This can help improve blood flow in patients with obstructive HCM.
The FDA’s decision was supported by results from the Phase 3 SCOUT-HCM clinical trial, which evaluated mavacamten in adolescents with symptomatic obstructive HCM. The study found that treatment significantly reduced obstruction to blood leaving the heart compared with placebo.
Although the approval expands treatment choices, mavacamten requires careful monitoring. Patients receiving the medication must undergo regular heart assessments, and access is managed through a required safety program, or REMS.
The approval represents progress for children and families who have faced limited treatment options. It also underscores the importance of continued research into inherited heart conditions and therapies designed to meet the needs of younger patients.
As new treatments become available, ensuring eligible children can receive appropriate specialty care and timely access to prescribed therapies will be essential to translating medical advances into better outcomes.
